Vicarious Surgical (NYSE:RBOT – Get Free Report) had its price target decreased by Piper Sandler from $30.00 to $12.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Piper Sandler’s target price would indicate a potential upside of 140.48% from the stock’s current price.
Separately, Morgan Stanley decreased their price target on shares of Vicarious Surgical from $18.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Monday, July 15th.
Get Our Latest Report on Vicarious Surgical
Vicarious Surgical Trading Down 9.3 %
Institutional Inflows and Outflows
An institutional investor recently raised its position in Vicarious Surgical stock. SRS Capital Advisors Inc. lifted its position in shares of Vicarious Surgical Inc (NYSE:RBOT – Free Report) by 215.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 87,905 shares of the company’s stock after acquiring an additional 60,000 shares during the period. SRS Capital Advisors Inc. owned approximately 0.07% of Vicarious Surgical worth $32,000 as of its most recent filing with the Securities and Exchange Commission. 47.27% of the stock is owned by institutional investors.
Vicarious Surgical Company Profile
Vicarious Surgical Inc operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Read More
- Five stocks we like better than Vicarious Surgical
- 3 REITs to Buy and Hold for the Long Term
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- High Dividend REITs: Are They an Ideal Way to Diversify?
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- Why Are These Companies Considered Blue Chips?
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Receive News & Ratings for Vicarious Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vicarious Surgical and related companies with MarketBeat.com's FREE daily email newsletter.